Gavi
The Vaccine Alliance

Kenya

Support for Vaccine: Yellow Fever

This Decision Letter sets out the Programme Terms of a Programme

This Decision Letter forms part of the Partnership Framework Agreement and together with the Partnership Framework Agreement sets out the Programme Terms of the Programme. Any term used in this Decision Letter but not defined shall have the meaning given to such term in the Partnership Framework Agreement. The English language version of this Decision Letter shall prevail in the case of any conflict with terms expressed in any other language.

1. Country: Kenya

2. Vaccine grant number: KEN-YF-R

3. Date of Decision Letter[1]: 19 April 2023

4. Date of the Partnership Framework Agreement (the "PFA"): 25 November 2014

5. Programme title: New Vaccine Support (NVS), Yellow Fever, Routine

6. Requested product presentation and formulation of vaccine:

YF, 10 doses/vial, lyophilised

7. Programme duration[2]: 2001-2026

8. Annual Amounts: (subject to the terms of the PFA)

This is the total amount approved by Gavi for the entire duration of the programme. Annual amounts are defined as per section 4.1 of the PFA. The annual amounts are indicative and not limited for use for the specified year. Any requested adjustments to the Annual Amounts will be subject to Gavi approval. It is essential that Country's Health Sector Coordination Committee (or its equivalent) be involved with this process both in its technical process function and its support during implementation and monitoring of the Programme. Further, amounts are indicative and are subject to the availability of funds and relevant approvals by the Gavi Board.

	2001-2021	2022	2023	2024	2025	2026	Total
Annual Amounts (US$)	1,243,604	188,319	144,499	118,311	-	-	1,694,734

[1] This Decision Letter will apply for the programme duration. Gavi will only update this Decision Letter in the event of the following: i) release of future year approvals; ii) adjustments to initial quantities; iii)product price changes or product switches; and/or iv) co-financing amounts.

[2] This is the entire duration of the programme.

9. Vaccine introduction grant:

Approval		
Year	**Grant number**	**Amount (US$)**
2002	KEN-YF-R-VIG-MOH	50,000
2018	KEN-YF-R-VIG-UNIC	107,838

10. Product switch grant:

Not applicable

11. Indicative annual amounts: (subject to the terms of the PFA)

Gavi Support	2001 - 2021	2022		2023		2024		2025		2026	
Material		**Units**	**Total Cost (US$)**	**Units**	**Total Cost (US$)**	**Units**	**Total Cost (US$)**	**Units**	**Total Cost (US$)**	**Units**	**Total Cost (US$)**
YF, 10 doses/vial, lyophilised		130,700	152,919	89,000	111,250	88,300	110,375	-	-	-	-
Syringe, A-D 0.5ml		86,200	3,103	39,600	2,222	39,400	2,210	-	-	-	-
Syringe, Re-constitution		14,400	605	9,800	508	9,700	502	-	-	-	-
Safety Box		1,100	516	550	421	550	421	-	-	-	-
Freight costs - doses		1	6,447	2	4,521	2	4,486	-	-	-	-
Freight costs - devices		1	422	2	319	2	317	-	-	-	-
Total amounts (US$)	***1,243,604***		***164,012***		***119,240***		***118,311***		-		-

12. Procurement agency:

UNICEF Supply Division. The Country shall release its co-financing payments each year to UNICEF Supply Division.

13. Self-procurement:

Not applicable

14. Co-financing obligations (indicative)[3]:

According to the co-financing policy, the Country falls within the group:	**Accelerated transition**

[3] *Gavi may adjust the outlined co-financing obligations based on the corresponding actual dose shipments to the country. Any over/under co-financed doses/amounts will be settled in subsequent payments.*

Global Health Campus, Ch. du Pommier 40
1218 Grand-Saconnex, Geneva, Switzerland
Tel. + 41 22 909 65 00
Fax + 41 22 909 65 50
www.gavi.org
info@gavi.org

Gavi
The Vaccine Alliance

Co-Finance Obligation	2022		2023		2024		2025		2026	
Material	**Units**	**Total Cost (US$)**	**Units**	**Total Cost (US$)**	**Units**	**Total Cost (US$)**	**Units**	**Total Cost (US$)**	**Units**	**Total Cost (US$)**
YF, 10 doses/vial, lyophilised	18,200	21,294	26,100	32,625	39,300	49,125	-	-	-	-
Syringe, A-D 0.5ml	12,000	432	11,800	662	17,600	987	-	-	-	-
Syringe, Re-constitution	2,000	84	2,900	150	4,400	228	-	-	-	-
Safety Box	175	82	175	134	250	191	-	-	-	-
Freight costs - doses	1	895	1	4,825	1	7,263	-	-	-	-
Freight costs - devices	1	59	1	96	1	142	-	-	-	-
Total Co-Financing ($USD) expected		***22,846***		***38,492***		***57,937***		-		-

15. Operational support for campaigns:

Not applicable

16. Additional Reporting Requirements:

Reports and other information :	Due dates
To enable the annual release of purchase orders, Country shall report closing stock levels by 31st March of each calendar year.[4]	31 March
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat

17. Financial clarifications:

Not applicable

18. Other conditions:

.

Colette Selman
Director, CPD - Core Countries
04 May 2023

[4] *Reporting requirements are subject to change. Countries may be required to submit quarterly or monthly stock reports. Country will be notified of updated reporting requirements separately.*

Global Health Campus, Ch. du Pommier 40
1218 Grand-Saconnex, Geneva, Switzerland
Tel. + 41 22 909 65 00
Fax + 41 22 909 65 50
www.gavi.org
info@gavi.org